Fludarabine
Estrogen Receptor-positive Breast Cancer
Fred Hutchinson Cancer CenterSmall moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 81/ 100
Competitive context
13 Active assets in the Estrogen Receptor-positive Breast Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
TAMOXIFEN Dana-Farber Cancer Institute | Phase 4 | BB |
Cyclophosphamide UNC Lineberger Comprehensive Cancer Center | Phase 2 | BB |
Inno-206 Baylor Breast Care Center | Phase 2 | BB |
FULVESTRANT Olema Pharmaceuticals, Inc. | Phase 3 | BB |
TRASTUZUMAB Dana-Farber Cancer Institute | Phase 3 | BB |
View all 30 →
Same molecule, other indications
Fludarabine is also rated in:
acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant
BBB
Indicative ·
76 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →